Atle Fund Management AB Buys 1,148 Shares of Intuitive Surgical, Inc. $ISRG

Atle Fund Management AB lifted its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 6.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 19,707 shares of the medical equipment provider’s stock after purchasing an additional 1,148 shares during the quarter. Intuitive Surgical makes up about 3.4% of Atle Fund Management AB’s investment portfolio, making the stock its 9th largest position. Atle Fund Management AB’s holdings in Intuitive Surgical were worth $8,814,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. SteelPeak Wealth LLC grew its holdings in shares of Intuitive Surgical by 28.7% in the 3rd quarter. SteelPeak Wealth LLC now owns 41,993 shares of the medical equipment provider’s stock valued at $18,781,000 after buying an additional 9,364 shares during the period. Amalgamated Bank increased its position in shares of Intuitive Surgical by 2.2% in the second quarter. Amalgamated Bank now owns 81,542 shares of the medical equipment provider’s stock valued at $44,311,000 after acquiring an additional 1,772 shares during the last quarter. Bessemer Group Inc. boosted its holdings in shares of Intuitive Surgical by 89.3% in the 2nd quarter. Bessemer Group Inc. now owns 788,328 shares of the medical equipment provider’s stock valued at $428,386,000 after buying an additional 371,806 shares during the last quarter. Sax Wealth Advisors LLC increased its stake in shares of Intuitive Surgical by 218.1% during the 2nd quarter. Sax Wealth Advisors LLC now owns 2,456 shares of the medical equipment provider’s stock worth $1,334,000 after purchasing an additional 1,684 shares during the last quarter. Finally, World Investment Advisors lifted its position in shares of Intuitive Surgical by 238.3% in the third quarter. World Investment Advisors now owns 5,399 shares of the medical equipment provider’s stock valued at $2,415,000 after buying an additional 3,803 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, SVP Mark Brosius sold 464 shares of Intuitive Surgical stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $548.49, for a total transaction of $254,499.36. Following the completion of the sale, the senior vice president owned 131 shares of the company’s stock, valued at $71,852.19. The trade was a 77.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Myriam Curet sold 126 shares of the company’s stock in a transaction on Thursday, January 29th. The shares were sold at an average price of $520.02, for a total transaction of $65,522.52. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 75,683 shares of company stock valued at $42,066,425. 0.70% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. HSBC upped their target price on Intuitive Surgical from $644.00 to $653.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Mizuho set a $575.00 price objective on Intuitive Surgical in a research report on Wednesday, October 22nd. BTIG Research reissued a “buy” rating and issued a $616.00 price target on shares of Intuitive Surgical in a research note on Friday, January 23rd. The Goldman Sachs Group reaffirmed a “buy” rating and set a $714.00 target price on shares of Intuitive Surgical in a research note on Friday, January 9th. Finally, Argus boosted their target price on Intuitive Surgical from $600.00 to $630.00 in a research report on Monday, October 27th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $620.41.

Trending Headlines about Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: TD Cowen upgraded ISRG and said the company’s long‑run growth is likely underestimated, supporting a higher multi‑year earnings outlook and raising optimism among growth investors. Intuitive Surgical Inc.’s (ISRG) long-run growth underestimated, says TD Cowen
• Positive Sentiment: Q4/earnings-call takeaways: analysts pressed management on growth drivers and margin outlook, but the quarter showed solid revenue and EPS beats that underpin the company’s recurring parts & services revenue model. That confirms continued demand for da Vinci systems and supports forward estimates. 5 Revealing Analyst Questions From Intuitive Surgical’s Q4 Earnings Call
• Positive Sentiment: Regulatory/product progress: coverage of cardiac clearance work and the rollout of the da Vinci 5 platform suggests new procedure types and market expansion that could lift system sales and higher‑margin consumables over time. Intuitive Surgical’s Cardiac Clearance Tests Valuation As da Vinci 5 Expands
• Positive Sentiment: Analyst/bull commentary: sector bulls and outlets (e.g., Zacks) remain positive on the da Vinci franchise and recurring revenue stream, reinforcing investor conviction on long‑term durability. Bull of the Day: Intuitive Surgical (ISRG)
• Neutral Sentiment: Valuation debate persists: retail analyst pieces note 2025 results were strong but warn the stock’s premium valuation is the main risk — strong fundamentals vs. expensive multiples keeps investor views mixed. Should You Buy Shares of Intuitive Surgical In February?
• Negative Sentiment: Insider selling: EVP Myriam Curet sold small blocks of ISRG shares in recent transactions (e.g., 126 shares at ~$520). The amounts are modest but such filings can create short‑term selling pressure or signal personal diversification. Intuitive Surgical (NASDAQ:ISRG) EVP Myriam Curet Sells 126 Shares

Intuitive Surgical Stock Performance

Shares of Intuitive Surgical stock opened at $504.22 on Friday. The stock has a market capitalization of $180.75 billion, a P/E ratio of 63.91, a P/E/G ratio of 3.92 and a beta of 1.67. Intuitive Surgical, Inc. has a 52-week low of $425.00 and a 52-week high of $609.08. The stock’s 50-day simple moving average is $558.64 and its 200 day simple moving average is $511.63.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, January 22nd. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.27 by $0.26. Intuitive Surgical had a return on equity of 15.06% and a net margin of 28.38%.The business had revenue of $2.87 billion for the quarter, compared to analysts’ expectations of $2.72 billion. During the same quarter in the prior year, the firm posted $2.21 EPS. The firm’s quarterly revenue was up 18.8% on a year-over-year basis. Equities research analysts forecast that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.